Jan 6, 2025 · Significant advancements in lung cancer treatment were seen throughout 2024, from new drug approvals to promising clinical trial results. Here are some of the top developments covered by Targeted Oncology TM, highlighting the progress in targeted therapies and improved patient outcomes.. FDA Approval of Ensartinib for ALK-Positive NSCLC: The FDA approved ensartinib for the first-line treatment ...

Dec 23, 2024 · In 2024, several significant advancements in breast oncology were covered by Targeted Oncology TM. Here are the top 10 developments from the year: FDA Approval of Inavolisib for Advanced Breast Cancer: The FDA approved inavolisib (Itovebi, previously GDC-0077) plus palbociclib (Ibrance) and fulvestrant for the treatment of hormone receptor–positive (HR+), HER2-negative (HER2-), PIK3CA ...

Jun 24, 2024 · Dostarlimab-gxly (Jemperli), a PD-1 inhibitor and immunotherapy drug, has shown remarkable potential in the treatment of patients with colorectal cancer, specifically in those with locally advanced mismatch repair-deficient (dMMR) rectal cancer.

Sep 25, 2024 · Recent trends have brought GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), to front of mind when discussing general weight loss. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, multiple presentations focused on the weight loss aspect of GLP-1 agonists for patients with breast cancer.

Oct 8, 2024 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma (HNSCC), meeting the primary end point of the phase 3 KEYNOTE-689 study (NCT03765918). 1 “These results are substantial, as KEYNOTE-689 marks the first positive trial in 2 decades for patients with resected, locally advanced head ...

Oct 2, 2024 · FDA Grants Fast Track Designation to ICT01 Plus Azacitidine and Venetoclax in AML. ICT01, a humanized anti-BTN3A monoclonal antibody, plus azacitidine and venetoclax (Venclexta) earned fast track designation for the treatment of acute myeloid leukemia in patients 75 or older or those who have comorbidities that preclude standard induction chemotherapy on …

Jan 10, 2025 · CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising critical questions about their clinical benefit. Vusolimogene oderparepvec plus nivolumab showed responses ...

Dec 23, 2024 · The FDA has granted priority review to the new drug application (NDA) for taletrectinib, a treatment for patients with ROS1-positive advanced non–small cell lung cancer (NSCLC).; This review follows promising data from 2 pivotal phase 2 trials, TRUST-1 (NCT04395677) and TRUST-II (NCT04919811).

Dec 15, 2024 · Zenocutuzumab Gains Gold With FDA Approval in NSCLC and Pancreatic Cancer. Zenocutuzumab (formerly MCLA-128) has received FDA approval for the treatment of patients with neuregulin 1 fusion (NRG1+) non–small cell lung cancer (NSCLC) and NRG1+ pancreatic ductal adenocarcinoma (PDAC).This approval is based on data from the open-label, multicenter, dose-escalation phase 1/2 eNRGy trial ...

Dec 23, 2024 · Dual immune checkpoint inhibition with nivolumab (Opdivo) and ipilimumab (Yervoy) shows promise for the treatment of anaplastic thyroid cancer (ATC), but offers limited benefit for those with radioiodine refractory differentiated thyroid carcinoma (RAIR DTC), according to findings from a phase 2 study (NCT03246958). 1 The study sought to evaluate the efficacy of these immunotherapies in ...